Načítá se...

Severe Delayed-Onset Neutropenia Induced by Ocrelizumab

BACKGROUND: Ocrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS). The adverse event profile is still being determined through postmarketing surveillance and case reports. OBJECTIVE: To report a case of sev...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurohospitalist
Hlavní autoři: Baird-Gunning, Jonatha, Yun, James, Stevenson, William, Ng, Karl
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8022193/
https://ncbi.nlm.nih.gov/pubmed/33868559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1941874420936438
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!